E - Glenmark

India Formulations
Current Status: FY 2006
Revenue growth of 30% over FY 2005, 39% growth in March 2006 [ORG-
IMS]
Ranked #2 in dermatology (after GSK), strong presence in over 10
segments including female healthcare, paediatrics, respiratory, antiinfectives,
cardiovascular, diabetology
Increased focus on chronic lifestyle diseases
Launched 45 new products and novel combinations including 15 first
generics such as Strontium Ranelate, Diacerin, Eplerenone, Acitretin, S-
ibuprofen
Created 7 retail divisions, 1 institutional division for improved focus
Grew field force (currently 1700 medical representatives) and increased
focus on productivity improvements
Driving supply chain cost down; new plant at Baddi for tax-efficiencies
Commenced in-licensing and co-marketing tie-ups for novel products